NCT05022342 - Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Breast Cancer

Interventions

OTHER

alpelisib plus fulvestrant

Prospective observational study. There is no treatment allocation. Patients administered alpelisib plus fulvestrant, that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (8)

110092

RECRUITING

Novartis Investigative Site, New Delhi

160055

RECRUITING

Novartis Investigative Site, Chandigarh

400071

RECRUITING

Novartis Investigative Site, Mumbai

411004

RECRUITING

Novartis Investigative Site, Pune

700016

RECRUITING

Novartis Investigative Site, Kolkata

700063

RECRUITING

Novartis Investigative Site, Kolkata

751005

RECRUITING

Novartis Investigative Site, Bhubaneswar

751007

RECRUITING

Novartis Investigative Site, Bhubaneshwar